HCA Healthcare, Inc.
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at HCA Healthcare, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 361.30 $ to 545.10 $ · Last price: 429.00 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Medical Care Facilities
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| HCA Healthcare, Inc. HCA | 95.2 | 15.2 | 9.0 | 42.6 | 15.0 | 7.1 | 8.2 |
| Tenet Healthcare Corporation THC | 22.6 | 14.0 | 5.8 | 41.7 | 17.9 | 3.1 | 42.8 |
| Encompass Health Corp EHC | 12.2 | 21.3 | 9.8 | 43.9 | 19.0 | 10.5 | -0.2 |
| DaVita HealthCare Partners Inc DVA | 11.7 | 18.1 | 8.9 | 32.4 | 13.9 | 6.5 | 43.0 |
| Universal Health Services Inc UHS | 10.9 | 7.9 | 5.5 | 44.6 | 11.2 | 9.7 | -3.1 |
| The Ensign Group Inc ENSG | 10.2 | 29.2 | 19.3 | 16.6 | 9.0 | 18.7 | 5.6 |
| Chemed Corp CHE | 6.7 | 29.8 | 15.7 | 33.1 | 12.9 | 4.1 | 11.2 |
| PACS Group, Inc. PACS | 6.5 | – | 20.3 | 17.3 | 8.5 | 29.3 | 274.9 |
| Lifestance Health Group Inc LFST | 4.8 | 204.7 | 39.5 | 33.6 | 5.5 | 13.9 | 144.9 |
| Median of companies shown | 10.9 | 19.7 | 9.8 | 33.6 | 12.9 | 9.7 | 11.2 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 41,490 | 6,198 | 2,890 | 7.30 | 5,653 | -5,633 | 33,758 |
| 2017 | 43,614 | 6,057 | 2,216 | 5.95 | 5,426 | -4,995 | 36,593 |
| 2018 | 46,677 | 6,642 | 3,787 | 10.66 | 6,761 | -2,918 | 39,207 |
| 2019 | 51,336 | 7,218 | 3,505 | 10.07 | 7,602 | -565 | 45,058 |
| 2020 | 51,533 | 7,262 | 3,754 | 10.87 | 9,232 | 2,892 | 47,490 |
| 2021 | 58,752 | 9,678 | 6,956 | 21.16 | 8,959 | 1,489 | 50,742 |
| 2022 | 60,233 | 9,053 | 5,643 | 19.15 | 8,522 | -73 | 52,438 |
| 2023 | 64,968 | 9,627 | 5,242 | 18.96 | 9,431 | 1,060 | 56,211 |
| 2024 | 70,603 | 10,547 | 5,760 | 22.00 | 10,514 | 555 | 59,513 |
| 2025 | 75,600 | 11,965 | 6,784 | 29.40 | 12,636 | -2,771 | 60,720 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 5.63 | -5.00 | 18,285 | 5.70 | 7.90 | 2,559 | 1,274 |
| 2025: Q1 | 6.45 | 8.70 | 18,321 | 5.70 | 8.80 | 1,651 | 660 |
| 2025: Q2 | 6.83 | 23.50 | 18,605 | 6.40 | 8.90 | 4,210 | 3,034 |
| 2025: Q3 | 6.78 | 38.70 | 19,161 | 9.60 | 8.60 | 4,416 | 3,128 |
| 2025: Q4 | 8.14 | 44.50 | 19,513 | 6.70 | 9.60 | 2,359 | 870 |
| 2026: Q1 | 7.15 | 10.70 | 19,109 | 4.30 | 8.50 | 2,014 | 895 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Aktien.Guide
Dividends
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 29.49 | 28.62 – 30.41 | 78,513 | 4.5% | 22 |
| 12/31/2027 | 32.07 | 30.30 – 34.04 | 81,632 | 8.7% | 22 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.
Today’s market value implies roughly 4.6% growth in free cash flow per year over ten years (assumptions: discount rate 10.0%, terminal growth 2.5%).
| Free cash flow (last twelve months) | $6.00B |
|---|---|
| Market cap | $95.16B |
| Free cash flow in year ten | $9.36B |
| Terminal value as a share of market value | 51.8% |
For comparison: over the past five years free cash flow grew by 3.8% per year.
It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 7.9%
- More than 10% revenue growth is expected for the coming year 4.8%
- Share count grows by less than 3% a year -7.8%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 17.3%
- Gross margin at 40% or higher and without meaningful erosion 41.5%
- Goodwill from acquisitions does not grow faster than revenue 16.9%
- Net debt below twice EBITDA 3.1 x EBITDA
- Operating cash flow covers the profits of the last three years 14,795 m
- Return on capital at 15% or higher, or up versus two years ago 27.0%
- Insiders hold at least 10% or are net buyers 16.2%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
6/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 6.9%
- Exp. sales growth 3Y > 5% 3.9%
- EBIT growth 10Y > 5% 7.6%
- Exp. EBIT growth 3Y > 5% 4.4%
- Net debt < 4x EBIT 4.0x
- EBIT positive, 10Y straight 10
- Max. EBIT decline < 50% 6.5%
- Return on equity > 15% –
- ROCE > 15% 27.0%
- Expected return > 10% 12.9%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 26, 2026 | McAlevey Michael R | EVP & Chief Legal & Admin Off. | Other | 7,769 | 429.00 | 3,332,901 |
The company
About the Company
HCA Healthcare, Inc. bietet über ihre Tochtergesellschaften Gesundheitsdienste in den USA an.
- Employees
- 230,000
- Headquarters
- Nashville, TN
- Address
- One Park Plaza, 37203 Nashville, United States
- Phone
- 615 344 9551
- Website
- hcahealthcare.com
- IPO Date
- 03/10/2011
- ISIN
- US40412C1018
Management
| Name | Title | Birth Year |
|---|---|---|
| Samuel N. Hazen | CEO & Director | 1960 |
| Michael A. Marks | CFO & Executive VP | 1970 |
| Jon Mack Foster | Executive VP & COO | 1962 |
| Michael R. McAlevey | Executive VP and Chief Legal & Administrative Officer | 1964 |
| Michael S. Cuffe M.B.A., M.D. | Executive Officer | 1966 |
| Thomas F. Frist Jr., M.D. | Founder & Chairman Emeritus | 1939 |
| Christopher F. Wyatt | Senior VP, Principal Accounting Officer & Controller | 1978 |
| Chad J. Wasserman | Senior VP & Chief Information Officer | – |
| Frank George Morgan C.F.A. | Vice President of Investor Relations | – |
| Wendy Warren | Senior VP and Chief Ethics & Compliance Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 07/29/2026 HCA Healthcare, Inc. (HCA): Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Other Events SEC ↗
- 07/24/2026 HCA Healthcare, Inc. (HCA): Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events; Financial Statements and Exhibits SEC ↗
- 07/14/2026 HCA Healthcare, Inc. (HCA): Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.